Navigation Links
Insmed Announces First Quarter 2008 Financial Results
Date:5/8/2008

> Accrued project costs & other 515 503

Payroll liabilities 799 631

Interest payable 20 23

Deferred rent 115 115

Deferred income 271 245

Convertible debt 2,211 2,211

Debt discount (865) (950)

Net convertible debt 1,346 1,261

Total current liabilities 3,870 3,682

Long-term liabilities:

Convertible debt 2,211 2,764

Debt discount (476) (651)

Net long-term convertible debt 1,735 2,113

Asset retirement obligation 2,217 2,217

Total liabilities 7,822 8,012

Stockholders' equity:

Common stock; $.01 par value; authorized

shares 500,000,000; issued and outstanding

shares, 121,904,312 1,219 1,219

Additional paid-in capital 341,403 341,270

Accumulated deficit (335,632) (330,759)

Accumulated other comprehensive loss:

Unrealized loss on investment - (242)

Net stockholders' equity 6,990 11,488

Total liabilities and stockholders' equity $14,812 $19,500

INSMED INCORPORATED

Consolidated Statements of Operations

(in thousands, except per share data - unaudited)

Three Months Ended


'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Insmed Appoints Dennis M. Lanfear to Board Of Directors
2. Insmed Awarded $2.1 Million by Muscular Dystrophy Association
3. Insmed to Appeal Delisting Notification From Nasdaq
4. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
5. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
6. Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
7. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
8. Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
9. Insmed Announces Additional Information in Compliance With NASDAQ Rules
10. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
11. Insmed to Present at CBI Follow-On Biologics Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...ov. 6 Helix BioPharma Co...nnounced that John Docherty, president and chief o...Ford,s 6th annual Investor Summit on November 10, ...ity. Mr. Docherty will provide an overview of the...DOS47 and Topical Interferon Alpha-2b. The slide ...
(Date:11/6/2009)...a, November 6 EUCODIS Bioscience, ...and marketing enzymes for the,chemical industry an...agreement with Bio Sidus, the leading biopharmaceu...eement gives EUCODIS Bioscience exclusive access -...dus, proprietary collection of,psychrophilic bacte...
(Date:11/6/2009)...if., Nov. 6 Calbiotech, Inc. annou...ss Innovative Research (SBIR) Phase I contract by ...d. Under terms of the agreement, Calbiotech will d...agnosis of Dengue virus. ,, Dengue virus is ... threat to military forces deployed to tropical ar...
(Date:11/6/2009)...ov. 6 Intarcia Therapeutics, Inc. ...(DUROS® continuous delivery of exenatide) pro...inth Annual Diabetes Technology Meeting in San Fra...gi-bin/prnh/20050301/SFTU126LOGO ) ,, Continu...0 Lowers Plasma Glucose, HbA1c and Reduces Weight ...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5
...tunities, Acknowledgement for Innovative,Thinking,...e and Science is Rec...h,consecutive year, Abbott (NYSE: ABT ) has been ...gazine 2007 Top Biotech and Pharma Employer,s,surv...se of businesses. To,enhance the experience for re...
... to the IEP,s Rollout in August 2008, AUSTIN, Tex...ustry observers to be one of the most innovative t...pharmaceutical industries,announced here today at ...eeting, its intent to organize and develop real-ti... use by spine fellows for the 2008 enrollment,year...
...n Innovative Solution in Efforts to ... Ohio, Oct. 24 STERIS Corporation,(NYSE: STE ) a...r its,VaproSure(TM) Room Sterilizer from several U...porates STERIS patented technologies and is the fi... Since being introduced in,June of this year, syst...
Other Biology Technology:Abbott Named to Science Magazine's List of 'Top Employers' in the Biotech and Pharmaceutical Industry 2Abbott Named to Science Magazine's List of 'Top Employers' in the Biotech and Pharmaceutical Industry 3Magnifi Group Demonstrates Industry's First Interactive Educational Program (IEP) for Spine Fellows 2Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against 'Superbugs' 2Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against 'Superbugs' 3Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against 'Superbugs' 4Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against 'Superbugs' 5Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against 'Superbugs' 6
(Date:11/4/2009)...E, Nov. 4 Glencoe Software, Inc., ...ent (OME) Consortium ( http://openmicroscopy.org ...e American Society of Cell Biology,s exciting new ...SCB has been awarded a $2.5M stimulus grant throug...Opportunities program, as part of the American Rei...
(Date:11/3/2009)..., SPAINIn a research report published in a recent ...ias and Sim Alegre examined the effects of coverin...lor, fruit quality, canopy light distribution, orc...ts were performed using Extenday and Solarmate fil...orchards of ,Mondial Gala, apples. The research sh...
(Date:11/3/2009)...s from the UCLA Henry Samueli School of Engineerin...essfully reconstituted in the laboratory the enzym...terol-lowering drug lovastatin. , The researc...ld potentially lead to the development of other co...The lovastatin-synthesizing enzyme is one of the m...
Breaking Biology News(10 mins):Glencoe Software to Support the ASCB 'Stimulus Grant' to Build Virtual Image Library of the Cell 2Reflective film can boost profits for apple growers 2UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin 2St Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients Heart Structures 4700 1St Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients Heart Structures 4700 2St Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients Heart Structures 4700 3Tianyin Pharmaceutical Co Inc Announces Cash Dividend to Common Stockholders 12933 1Tianyin Pharmaceutical Co Inc Announces Cash Dividend to Common Stockholders 12933 2The Max Cure Foundation Announces Its First Charity Benefit 3A The Roar for a Cure Carnival to Be Held on Saturday August 22 2009 51038 1The Max Cure Foundation Announces Its First Charity Benefit 3A The Roar for a Cure Carnival to Be Held on Saturday August 22 2009 51038 2The Max Cure Foundation Announces Its First Charity Benefit 3A The Roar for a Cure Carnival to Be Held on Saturday August 22 2009 51038 3The Max Cure Foundation Announces Its First Charity Benefit 3A The Roar for a Cure Carnival to Be Held on Saturday August 22 2009 51038 4The Max Cure Foundation Announces Its First Charity Benefit 3A The Roar for a Cure Carnival to Be Held on Saturday August 22 2009 51038 5
...ns McKusick-Nathans Institute of Genetic Medicine ...n to win a new $11.7 million four-year federal gra...actors as diet, exercise, stress and addictions in...ffect their risk for disorders as wide-ranging as ..., The Johns Hopkins Center for Inherited Disease ...
... Calif. Cheryl Hayashi, a biologist at UC Riversi...of spider silk, has won a $500,000 MacArthur Fello...ountry. She is one of only 24 MacArthur Fellows f...rthur Foundation. , Commonly known as a genius aw...ched grant to individuals who show exceptional cre...
...rk , Many herbal plants such as strawberry, clover...ndividual plants remain connected with each other ...These connections enable the plants to share infor... are therefore very similar to computer networks. ...t? , Recently Stuefer and his colleagues were the...
Other Biology News:'Genes and environment' grant funds close look at nature-nurture overlap in common diseases 2'Genes and environment' grant funds close look at nature-nurture overlap in common diseases 3UC Riverside biologist receives prestigious MacArthur Fellowship 2UC Riverside biologist receives prestigious MacArthur Fellowship 3
Multi-Chamber Dispenser from Terra Universal, Inc.
...expression profiling and built on the flexible and...latform. These microarrays are available as part o...Service. Probe Content The Rice microRNA Microa...mature sequences). The comprehensive probe content...
...ometer with a minimum 1 nm resolution and a highes...an band of water. ,The FP-6500 is especially desig...in biochemistry as kinetics, stopped-flow, titrati...esigned to keep GLP/GMP compliance in mind. Built-...
...expression profiling and built on the flexible and...latform. These microarrays are available as part o...Service. Probe Content The Fishes microRNA Micr...ue mature sequences). The comprehensive probe cont...
Biology Products: